Quantcast

Latest Adaptive Biotechnologies Corporation Stories

2015-01-07 12:27:37

Deal Expected to Expedite the Development and Commercialization of Immunosequencing Applications SEATTLE, Jan.

2014-12-02 12:31:08

Data Validates Clinical Advantage of Tracking Minimal Residual Disease with the clonoSEQ(TM) Test in Patients with ALL, CLL, MM, DLBCL SEATTLE, Dec.

2014-11-26 12:25:34

immunoSEQ(TM) Next Generation Sequencing Assay Confirms Presence of Active Immune Response in Responders Prior to Treatment SEATTLE, Nov.

2014-11-24 16:25:26

First available immunosequencing Kit with validated bias control methodology to ensure data reliability SEATTLE, Nov.

2014-09-29 12:29:44

Highly distinguished advisory board to strengthen incorporation of Next Generation Sequencing (NGS) into clinical care for patients with blood cancers SEATTLE, Sept.

2014-07-08 12:28:58

SEATTLE, July 8, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is

2014-06-27 12:26:33

Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling SEATTLE,

2014-06-19 16:26:33

SEATTLE, June 19, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is


Word of the Day
definiens
  • The word or words serving to define another word or expression, as in a dictionary entry.
The word 'definiens' comes from the Latin word 'definire', 'to define'.
Related